Earnings Call Scheduled for 8:30 a.m. U.S. Eastern Time on Wednesday, May 21, 2025HONG KONG, May 14, 2025 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before U.S. markets open on Wednesday, May 21, 2025. Management will hold a conference call to discuss these results at 8:30 a.m. U.S. ...

Core Viewpoint - Innventure, Inc. is set to release its first quarter 2025 financial results on May 15, 2025, and will host a conference call to discuss these results [1]. Group 1: Financial Results Announcement - Innventure will announce its Q1 2025 financial results after market close on May 15, 2025 [1]. - A conference call will be held on the same day at 5:00 pm ET to discuss the financial results [1]. Group 2: Participation Details - Interested parties can join the teleconference by registering through a provided link, which will give them dial-in details and a unique PIN [2]. - Registration for the call is open until the live event, but early registration is recommended to ensure full participation [2]. Group 3: Company Overview - Innventure focuses on founding, funding, and operating companies that provide transformative, sustainable technology solutions acquired or licensed from multinational corporations [3]. - The company aims to commercialize breakthrough technologies, mitigating risks while building disruptive companies with a target enterprise value of at least $1 billion [3]. - "Disruptive" innovations are defined by Innventure as those that can significantly alter business operations, industries, markets, or consumer behavior [3].

Cover page Capstone Infrastructure MD&A and Financial Statements Q1 2025 Toronto, Ontario, May 13, 2025 (GLOBE NEWSWIRE) -- Capstone Infrastructure Corporation (TSX: CSE.PR.A) (the "Corporation" or "Capstone") today announced and filed its financial results for the first quarter ended March 31, 2025. The Corporation’s Management’s Discussion and Analysis ("MD&A") for the first quarter of 2025 and unaudited interim consolidated financial statements are available at www.capstoneinfrastructure.com and on S ...

BENCHTOP LAB EQUIPMENT SALES UP 5% FIRST PEER-REVIEWED PUBLICATION ON COMPANY’S DOTS MPS BIOPROCESSING PLATFORM RECORD NUMBER OF BIOPROCESSING SALES OPPORTUNITIES Investor Call to be held Wednesday, May 14th at 11:00 a.m. Eastern Time BOHEMIA, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- Scientific Industries, Inc. (OTCQB: SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, yesterday reported financial results for the three-month period ended March 31, 2025. Busin ...

MIAMI, May 13, 2025 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc, (NASDAQ: WRAP) (“Wrap” or, the “Company”), a global leader in innovative public safety technologies and non-lethal tools, today announces it plans to hold a conference call on Friday, May 16, 2025, at 9:15 a.m. Eastern Time (6:15 a.m. Pacific Time) to discuss its financial and operational results for the three months ended March 31, 2025. The financial and operational results are expected to be issued in a press release prior to the call. Wrap ...

Financial Performance - Revenue for the three months ended March 31, 2025, increased by $0.1 million, or 2%, to $3.4 million compared to $3.3 million for the same period in 2024, driven primarily by a $0.4 million increase in imagery ordered by Asset Monitoring customers, partially offset by a $0.4 million decrease in revenue from the Space Systems business line [5][10] - The company ended the quarter with $17.7 million in cash, a decrease from $22.5 million at the end of 2024, and reduced cash used in operations by $5.4 million, or 53%, compared to the same period in 2024 [4][10] - Net loss for the three months ended March 31, 2025, increased by $17.4 million to $32.6 million, compared to a net loss of $15.2 million for the same period in 2024, primarily due to an increase in the change in fair value of financial instruments [10][15] Cost Management - Cost of sales decreased by $0.1 million, or 5%, to $1.2 million for the three months ended March 31, 2025, driven by lower Space Systems costs, while selling, general, and administrative expenses decreased by $2.9 million, or 31%, to $6.5 million [5][10] - Engineering expenses decreased by $1.9 million, or 43%, to $2.5 million for the same period, attributed to workforce reductions and other expense control measures [5][10] Strategic Developments - The company completed its domestication to the U.S. and secured a $30 million contract for an AI-first constellation, alongside a $20 million registered direct offering, enhancing its liquidity position [2][3] - Management anticipates that revenue for 2025 will largely depend on closing opportunities within the Space Systems line of business, which is expected to contribute significant cash flow and strong gross margins [4][10] Non-GAAP Financial Measures - Non-GAAP Adjusted EBITDA loss for the three months ended March 31, 2025, improved by $3.1 million to $6.1 million from a loss of $9.1 million for the same period in 2024, primarily due to increases in revenue and decreases in operating expenses [10][12] - The company defines Non-GAAP EBITDA as net loss excluding interest, income taxes, depreciation, and amortization, with a reported Non-GAAP EBITDA loss of $29.2 million for the period [6][7]

Core Insights - GEN Restaurant Group, Inc. reported a strong start to 2025 with the opening of six new restaurants, including a dual-concept location in Austin, Texas, combining GEN Korean BBQ and Kan Sushi [4][8] - The company anticipates total revenue for the year to be between $245 million and $250 million, with a restaurant-level adjusted EBITDA margin projected between 17% and 18% [5][8] - Despite a cautious consumer spending environment, the company achieved a 13% increase in total revenue year-over-year for Q1 2025, reaching $57.3 million compared to $50.8 million in Q1 2024 [6][8] Financial Performance - Total revenue increased by 13.0% to $57.3 million in Q1 2025 compared to $50.8 million in Q1 2024 [6][8] - Restaurant-level adjusted EBITDA rose by 6.0% to $9.0 million from $8.4 million in the prior year [8] - The company reported a net loss before income taxes of $2.1 million, equating to $(0.06) per diluted share, compared to a net income of $3.8 million or $0.11 per diluted share in Q1 2024 [11][32] Operational Highlights - The company opened six new locations in Q1 2025, bringing the total to 49 locations across eleven states [8][25] - Comparable restaurant sales decreased by 0.7% in Q1 2025, a slight improvement from a 5.6% decline for all of 2024 [8][25] - The company has a robust development pipeline, aiming to open 12 to 13 new restaurants in fiscal 2025, including three international locations in South Korea [5][8] Cost and Expense Analysis - Total restaurant operating expenses as a percentage of revenue increased by 120 basis points to 88.0% in Q1 2025 from 86.8% in Q1 2024 [7][8] - General and administrative expenses increased to $5.6 million, or 9.8% of total revenue, reflecting increased personnel for new restaurant development and additional marketing expenditures [10][8] - Pre-opening expenses rose to $2.6 million in Q1 2025 from $1.9 million in Q1 2024 due to the opening of six new restaurants [17][8] Cash Position and Liquidity - As of March 31, 2025, the company had $15.4 million in cash and cash equivalents, with no material long-term debt and full access to a $20 million line of credit [13][8] - The company maintains a strong cash flow position, which supports its strategic priorities for growth [5][8]

Core Viewpoint - Intensity Therapeutics, Inc. reported its first quarter 2025 financial results and provided updates on its clinical studies, particularly focusing on the INVINCIBLE-3 and INVINCIBLE-4 studies for its lead product candidate INT230-6, which targets various cancer types [1][7]. Corporate Update - The INVINCIBLE-4 Study is a Phase 2 trial assessing the efficacy of INT230-6 in combination with standard of care for early-stage operable triple-negative breast cancer, with a primary endpoint of pathological complete response rate [2]. - The study is currently recruiting patients in Switzerland and is expected to enroll 54 patients across Switzerland and France, with authorization from the European Medicines Agency [3]. - The INVINCIBLE-3 Study is a Phase 3 trial evaluating INT230-6 as a monotherapy for certain soft tissue sarcoma subtypes, with a planned enrollment of 333 patients across eight countries [4]. - The Company paused new site activations and patient enrollments for the INVINCIBLE-3 Study due to funding constraints, having previously enrolled 23 patients [5]. Financial Results - For the first quarter of 2025, research and development expenses were $2.2 million, down from $2.8 million in the same period of 2024, while general and administrative expenses decreased to $1.2 million from $1.9 million [8][10]. - The overall net loss for the quarter was $3.3 million, an improvement from a net loss of $4.6 million in the first quarter of 2024 [11]. - As of March 31, 2025, the Company had cash and cash equivalents totaling $0.9 million, a decrease from $2.6 million at the end of 2024 [11][17]. Product Information - INT230-6 is designed for direct intratumoral injection and combines two anti-cancer agents, cisplatin and vinblastine, with a penetration enhancer to improve drug distribution within tumors [12]. - The drug aims to elicit both local tumor control and systemic immune responses without the immunosuppression typically associated with systemic chemotherapy [13].

Core Insights - Reed's, Inc. reported a 4.5% increase in net sales for Q1 2025, reaching $10.0 million compared to $9.6 million in Q1 2024, driven by higher volumes with national customers [6][10] - The company is focused on improving operational efficiency, having reduced short shipments from approximately 20% to roughly 2% in April 2025, and is now producing in line with demand [4][5] - The new CEO, Cyril Wallace, emphasizes a commitment to quality and operational excellence, aiming for sustainable growth across existing and new product lines [3][5] Financial Performance - Gross profit for Q1 2025 remained flat at $3.4 million, with a gross margin of 33.9%, down from 35.6% in the previous year, primarily due to increased costs of goods sold [7][10] - Delivery and handling costs increased to $1.6 million, representing 16.2% of net sales, compared to 15.7% in Q1 2024 [8][10] - Selling, general, and administrative expenses rose to $3.5 million from $2.6 million, reflecting investments in personnel and marketing [9][10] Loss and Cash Flow - The operating loss for Q1 2025 was $1.7 million, compared to a loss of $0.7 million in Q1 2024, with a modified EBITDA loss of $1.6 million versus a loss of $0.4 million in the prior year [9][11][30] - The company used approximately $5.4 million in cash from operating activities in Q1 2025, compared to $2.4 million in the same period of 2024 [12][30] - As of March 31, 2025, Reed's had approximately $4.9 million in cash and $9.6 million in total debt, down from $10.4 million in cash at the end of 2024 [12][30] Strategic Outlook - The management is in the early stages of refining a long-term strategic plan, focusing on building scale, improving margins, and returning to profitability [5] - The company is expanding its distribution of core products and launching new functional beverages, which are expected to contribute to meaningful results in 2025 [4][5]

Core Insights - Vaxart, Inc. has resumed screening for the 10,000 participant portion of its COVID-19 Phase 2b trial, with dosing expected to start in Q2 2025 [4][7] - The company completed enrollment for its Phase 1 clinical trial of a second-generation oral norovirus vaccine, with topline data anticipated in mid-2025 [4][7] - A new avian influenza vaccine candidate demonstrated 100% protection in a ferret challenge model, contrasting with 0% survival in placebo-treated animals [9] COVID-19 Vaccine Developments - The stop work order for the COVID-19 Phase 2b trial was lifted, allowing Vaxart to proceed with participant screening [4][7] - The company is operating under a Project NextGen award, potentially receiving up to $460.7 million, with $240.1 million currently available [7] - Screening for the trial is currently underway, with dosing expected to begin in the second quarter of 2025 [7] Norovirus Vaccine Developments - Vaxart completed enrollment of 60 participants in its Phase 1 trial for the second-generation oral norovirus vaccine, with results expected in mid-2025 [7] - An independent Data and Safety Monitoring Board recommended the continuation of the study without modifications [7] Avian Influenza Program Developments - The new avian influenza vaccine candidate showed 100% protection against death in a ferret model, with plans to publish the findings in a peer-reviewed forum [9] Financial Results - For Q1 2025, Vaxart reported revenue of $20.9 million, a significant increase from $2.2 million in Q1 2024 [12][18] - Research and development expenses rose to $30.7 million in Q1 2025, compared to $19.0 million in Q1 2024, primarily due to increased clinical trial costs [12][18] - The net loss for Q1 2025 was $15.6 million, an improvement from a net loss of $24.4 million in Q1 2024, with a net loss per share of $0.07 compared to $0.14 in the previous year [12][18][19] Leadership Changes - Jeroen Grasman has been appointed as Chief Financial Officer effective May 19, 2025, succeeding Phillip Lee, who will remain as a non-executive employee until June 1, 2025 [12]